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Abstract
Background
Personalized targeted treatment in metastatic breast cancer relies on accurate assessment
of molecular aberrations, e.g. overexpression of Human Epidermal growth factor Receptor
2 (HER-2). Molecular interrogation of circulating tumor cells (CTCs) can provide an attrac-
tive alternative for real-time biomarker assessment. However, implementation of Cell-
Search-based HER-2 analysis has been limited. Immunofluorescent (IF) image
interpretation is crucial, as different HER-2 categories have been described. Major ques-
tions in CTC research are how these IF categories reflect gene expression and amplifica-
tion, and if we should consider ‘medium’ HER-2 expressing CTCs for patient selection.
Methods
Tumor cells from spiked cell lines (n = 8) and CTCs (n = 116 samples) of 85 metastatic
breast cancer patients were enriched using CellSearch. Comparative analysis of HER-2
expression by IF imaging (ACCEPT, DEPArray, and visual scoring) with qRT-PCR and
HER-2/neu FISH was performed.
Results
Automated IF HER-2-profiling by DEPArray and ACCEPT delivered comparable results.
There was a 98% agreement between 17 trained observers (visual scoring) and ACCEPT
considering HER-2neg and HER-2high expressing CTCs. However, 89% of HER-2med
expressing CTCs by ACCEPT were scored negative by observers. HER-2high expressing
tumor cells demonstrated HER-2/neu gene amplification, whereas HER-2neg and HER-2med
expressing tumor cells and CTCs by ACCEPT were copy-number neutral. All patients with
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HER-2-positive archival tumors had�1 HER-2high expressing CTCs, while 80% of HER-2-
negative patients did not. High relative gene expression of HER-2 measured on enriched
CTC lysates correlated with having�1 HER-2high expressing CTCs.
Conclusion
Automated images analysis has enormous potential for clinical implementation. HER-2
characterization and clinical trial design should be focused on HER-2high expressing CTCs.
Introduction
Breast cancer is a heterogeneous disease, with distinct subgroups based on histological type,
grade, and hormone receptor status. Human epidermal growth factor receptor 2 (HER-2)
overexpression accounts for 10–15% of the primary invasive breast cancers and is associated
with a more aggressive phenotype and inferior prognosis. In patients with advanced disease,
clinically relevant discrepancies can arise in HER-2 expression status compared to the localized
setting [1–3]. Furthermore, patients often develop multiple lesions that might be composed of
various tumor subclones harboring different molecular characteristics [4]. As the HER-2 status
can be subjective to temporal heterogeneity, in part influenced by prior therapies, it stands to
reason that repeated analysis is a prerequisite for precision medicine. However, the acquire-
ment of metastatic tissue is not always feasible and not without risk for the patient [5].
Circulating Tumor Cells (CTCs), isolated from the blood of patients with metastatic cancer,
hold considerable promise to provide a convenient and safe alternative for real-time and
repeated tumor profiling. Before molecular characterization of CTCs can be used to discover
predictive biomarkers, e.g. HER-2 receptor status, in-depth testing of analysis methods is
essential. The CellSearch system is an FDA-cleared and widespread implemented platform for
enumeration of CTCs, and HER-2-positive CTCs have been detected using HER-2 immuno-
fluorescence (IF) phenotyping. Visual scoring of HER-2 on CellSearch IF images by individual
observers has been performed in several studies [6–8]. Image interpretation is crucial, espe-
cially when using CTCs in interventional trials testing HER-2-directed therapies. Although
trained observers can reach acceptable agreement using a predefined definition [9], visual
scoring is not objective and independent image review is laborious. Recently, an objective
analysis software for CellSearch IF images: Automated CTC Classification Enumeration and
PhenoTyping (ACCEPT) has been made available, which is able to divide CTCs in HER-2neg
(ative), HER-2med(ium), and HER-2high expression [8]. One major question in CTC research is
how these IF categories reflect gene expression and amplification. One study demonstrated
that HER-2-positive CTCs based on visual scoring were HER-2 gene amplified [10]. Still the
value of HER-2med expressing CTCs has to be studied, as patients harboring these CTCs might
as well benefit from HER-2-directed therapies. In this study we compare ACCEPT results with
other IF imaging, quantitative reverse transcription (qRT)-PCR, and fluorescent in-situ
hybridization (FISH).
Methods
The ethical committee of the Antwerp University Hospital (UZA) and University of Antwerp
(UA) approved this non-interventional study (UA A11-18). Images used in the observer study
were obtained from samples of patients enrolled in studies of the Erasmus Medical Center
HER-2 characterization on circulating tumor cells
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Rotterdam (METC 2016–313 and METC 2009–405). Informed written consent was obtained
from all patients. The raw data can be downloaded from S1 Dataset.
A detailed description of all materials and methods is provided in S1 Supplementary Meth-
ods. A schematic overview of all samples and the workflow is depicted in Fig 1.
Samples
The preclinical model utilizes eight breast cancer cell lines with increasing levels of HER-2
expression and/or amplification: MDA-MB-436, MCF-7, BT-20, MDA-MB-453, KPL-4, IBC-
3, SUM190, and SKBR-3 [8, 9, 11–16]. Cultured tumor cells were spiked in 7.5mL Cell Save-
collected healthy donor blood and subjected to the CellSearch CTC procedure (Menarini Sili-
con Biosystems Inc., Huntingdon Valley, PA, USA), with addition of the HER-2 phenotyping
reagent (Menarini Silicon Biosystems Inc.). Briefly, the CellTracks Autoprep immunomagneti-
cally enriches EpCAM-positive cells from blood and stains them with the nuclear dye DAPI,
phycoerythrin conjugated antibodies against cytokeratin 8, 18 and 19 (CK-PE) and allophyco-
cyanin conjugated antibody against the leukocyte specific marker CD45 (CD45-APC). The
enriched cells are contained in a cartridge. Similarly, CTCs were enriched from 7.5 ml blood
samples (n = 116) of 85 patients starting a new line of systemic therapy for metastatic breast
cancer (MBC), who were recruited between 2012 and 2015 at the Oncology Center of GZA
Hospitals Sint-Augustinus (Antwerp, Belgium), after written informed consent (Study UA
A11-18)(S1 and S2 Tables). In total, 45/116 (38.8%) samples contained�5 CTC/7,5 ml blood.
For the inter-observer concordance study, 17 international pathologist and scientists scored
2000 CellSearch HER-2-FITC thumbnail images of CTCs acquired from MBC patients who
were enrolled, after written informed consent, in CTC studies at the Erasmus MC (Rotterdam,
The Netherlands) (METC 2016–313 and METC 2009–405).
IF imaging
Image-based HER-2 fluorescent intensities were analyzed using three methodologies (S3
Table). First, visual scoring, which classifies the cells into negative, 2+, and 3+ was employed,
Fig 1. Schematic overview of samples and workflow.
https://doi.org/10.1371/journal.pone.0220906.g001
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as previously described [9]. Using an online survey platform, CellTracks Analyzer II thumbnail
images of CTCs (n = 2000) were reviewed by 17 international scientists and pathologists, who
were trained to perform the visual HER-2 scoring. The obtained scores were benchmarked
against the automated scoring results by ACCEPT [8]. ACCEPT was used to automatically
analyze the raw TIFF images of every fluorescent filter (DAPI, PE, APC, and FITC) taken by
the CellTracks Analyzer II (Menarini Silicon Biosystems Inc.) [8]. CTC identification and
HER-2 IF intensity classification (HER-2neg, HER-2med, and HER-2high) was performed with
gating and HER-2-FITC cut-off settings as previously described [8, 17]. Briefly, CTC gates are
defined as: Mean Intensity CD45� 5, Mean Intensity DNA> 45, Mean Intensity CK> 60,
16� Size CK� 400, DNA overlay CK > 0.2; and HER-2 cut-offs are: HER-2neg (Mean Inten-
sity HER-2 = 0), HER-2med (<100), and HER-2high (�100). Thirdly, to validate objective IF
scoring by ACCEPT, 7 CellSearch-enriched tumor cell lines and 4 CTC samples with high
count were transferred to the DEPArray V2 system (Menarini Silicon Biosystems Inc.), as we
have described previously [18]. Briefly, the loaded sample is automatically injected into the
microchamber of a cartridge where single cells are trapped in one of 16,000 electrical cages. IF
images of the entire surface area are taken and cells are automatically detected by the system,
generating an image library and 40 parameters per individual cell. HER-2 scoring was per-
formed using the relative fluorescent units (RFU) of the HER-2-FITC signal after background
subtraction (i.e. Mean Intensity-bgsub parameter). A cut-off for HER-2 positivity was defined
at>1185 RFUs. Using this cut-off, 95% of the analyzed cells within the theoretically expected
HER-2-positive and -negative cell lines classified as positive and negative, respectively.
FISH
A HER-2/neu FISH protocol was established using cell line models. CellSearch-enriched
tumor cells (8 spiked cell lines) and patient CTCs (4 samples) were spinned on a Superfrost
Plus slide (Fisherbrand) using a Slide carrier with a 1ml One-Funnel Cytochamber (cat. 1662
and 1663 resp., Hettich) and fixed in acetone at 4˚C for 5 minutes. FISH on slide was per-
formed using the DAKO IQFISH kit (Agilent), with adjusted protocol as described in S1 Sup-
plementary Methods. Before and after FISH, slides were scanned on the BioView scan device
with a specialized CTC protocol (BioView, Israel), in order to detect and map the tumor cells
in the leukocyte background. HER-2 status was assessed according to the manufactures guide-
lines (Agilent).
qRT-PCR
Besides HER-2 image analysis, CellSearch Profile-enriched tumor cell fractions (cell lines:
n = 7, patient samples: n = 54) were subjected to HER-2 expression analysis, as described pre-
viously [19]. Samples were taken simultaneously with CellSearch CTC samples, to facilitate
comparison between gene expression and IF. Briefly, 25% of the isolated RNA from the
enriched fraction was subjected to complementary DNA (cDNA) synthesis and pre-amplifica-
tion, using the RevertAid H Minus First Strand cDNA synthesis kit and TaqMan PreAmp
master mix, respectively (Thermo Fisher Scientific #K1632 and #4488593). Pre-amplified
cDNA was diluted 15x with 1xTE-buffer, after which qRT-PCR was performed for ERBB2 as
target gene, 3 housekeeping genes (SDHA, HMBS and HPRT1) to control for sample loading
and RNA integrity, epithelial (EPCAM, KRT19) and leukocyte (PTPRC) markers to control for
presence of epithelial and leukocyte content. ERBB2 Cq value of every sample was normalized
to the epithelial signal within that sample (dCq). All samples were further normalized to the
calibrator (ddCq).
HER-2 characterization on circulating tumor cells
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Statistics
Correlations between the HER-2 analysis methods ACCEPT, DEPArray, and qRT-PCR was
calculated using Pearson’s correlation coefficient. Fisher’s exact test was used to compare
ACCEPT and qRT-PCR results within HER-2-negative and HER-2-positive patient groups.
Results
HER-2 protein expression and gene amplification
HER-2 IF image interpretation is crucial, especially when using CTCs in interventional trials
testing HER-2-directed therapies. In our international observer study, 17 trained readers per-
formed visual HER-2 scoring (negative, or positive: 2+ or 3+) of 2000 patient-derived thumb-
nail CellSearch HER-2 images, which was compared to the new objective ACCEPT algorithm
(HER-2neg, HER-2med, and HER-2high). For 1535 CTCs (77%) a high concordance (i.e. >75%)
between observers was reached, which was predominantly driven by agreement on HER-2
negativity (Fig 2A). According to ACCEPT, 860 (43.8%) CTCs were HER-2neg, 608 (31.0%)
were HER-2med, and 495 (25.2%) were HER-2high expressing CTCs. 37 CTCs were not detected
by ACCEPT. When comparing the 1535 highly concordant scored CTCs with ACCEPT
results, observers tend to score HER-2 expression on these CTCs lower than ACCEPT does
(Fig 2B). Especially HER-2med expressing CTCs were frequently scored as negative cells by
observers. When merging the 2+ and 3+ scored CTCs into one HER-2-positive group, high
concordance (i.e. >75%) was reached for 1843/2000 (92%) CTCs. 460/468 (98%) HER-2high
expressing CTCs were scored as positive by the observers, and 816/831 (98%) HER-2neg CTCs
were scored negative by the observers. Again, ACCEPT HER-2med CTCs were scored negative
in 457/511 (89%) cases (Fig 2C). These dim expressing CTCs are covered in the negative cate-
gory of the visual scoring system, as it includes 0 and 1+ scores. Furthermore, there was a sig-
nificant difference between the mean IF intensity of the HER-2med CTCs scored negative (47.9
+/- 15.5) versus positive (82.1 +/- 13.1) on visual scoring. Inter-observer variability (Kappa
test) was 0.636 for visual scoring in negative, 2+, and 3+ groups, and 0.785 for scoring in nega-
tive versus positive groups, which are both considered as ‘good’ according to the Koch and
Landis classification [20]. Overall, we found high agreement between observers and ACCEPT
regarding HER-2neg and HER-2high expressing CTCs, however ACCEPT HER-2med CTCs
appear negative on visual scoring. To further investigate this, we performed IF image analysis
and FISH on a cell line model.
Two automated image analysis methods, i.e. DEPArray and ACCEPT, were used to mea-
sure HER-2 IF signal on CellSearch-enriched samples of eight breast cancer cell lines with
incremental HER-2-FITC intensity, categorized as HER-2neg (MCF-7, MDA-MB-436, and
BT-20), HER-2med (MDA-MB-453), and HER-2high (KPL-4, SUM190, IBC-3, and SKBR-3)
according to literature [8, 9, 13] (Fig 3A and 3B). ACCEPT analysis of CellSearch Analyzer II
raw images demonstrated absence of HER-2-FITC signal in 8409/8434 (99.7%) leukocytes and
496/509 (97.4%) negative cell line cells (Fig 3B). MDA-MB-453 cells were HER-2med express-
ing in 368/640 (57.5%), the rest being HER-2neg. Within the HER-positive cell lines KPL-4,
IBC-3, SKBR-3, and SUM190 we observed an incremental increase in the median HER-
2-FITC intensity, with 415/542 (76.6%), 187/212 (88.2%), 189/208 (90.9%) and 220/228
(96.5%) cells, respectively, being classified as HER-2high expressing cells (Fig 3B).
Overall, when comparing both DEPArray and ACCEPT cell line data, a comparable gradi-
ent in the mean HER-2 expression levels was observed (Pearson r = 0.96, p = 0.0001). As the
DEPArray system is able to recover individual CTCs, the found cut-off can be used to sort
samples into different HER-2 categories for downstream analysis.
HER-2 characterization on circulating tumor cells
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To infer whether increased HER-2-FITC IF signals find their origin in gene amplification,
we applied HER-2/neu FISH on the CellSearch-enriched fractions. In all samples, analyzed leu-
kocytes (n = 20) demonstrated a copy-number neutral HER-2/neu status (S1 Fig). A similar
observation was made in HER-2-negative cell lines MDA-MB-436, MCF-7, and BT-20,
Fig 2. HER-2 scoring of 2000 CTC thumbnail IF images by 17 trained observers (0, 2+, 3+) versus ACCEPT
(HER-2neg, HER-2med, HER-2high). A.�75% concordance between observers was reached for 1535 CTCs. For 358
CTCs agreement was reached between>50% of observers, and for 107 CTCs (dashed box) no agreement was reached
B. HER-2 scores of 1535 CTCs given by�75% of observers versus ACCEPT. HER-2-negative CTCs according to
observers were mainly scored HER-2neg or HER-2med by ACCEPT. HER-2high expressing CTCs by ACCEPT were
predominantly scored 2+ or 3+ by the observers. C. HER-2 scores of 1810 CTCs given by�75% of observers versus
ACCEPT. HER-2high expressing CTCs by ACCEPT were predominantly scored positive by the observers.
https://doi.org/10.1371/journal.pone.0220906.g002
Fig 3. HER-2 IF and FISH on a cell line model and 4 patient samples. A. HER-2 mean intensity background
subtracted (bgsub) for donor leukocytes, 3 HER-2-negative cell lines (MDA-MB-436, MCR-7, BT-20) and 4 HER-
2-posititve cell lines (KPL-4, IBC-3, SKBR-3, SUM190), and 4 patient samples measured by DEPArray. The cut-off
between HER-2-negative and -positive cells was defined at 1185 RFU. B. HER-2 mean intensities for donor leukocytes,
8 cell lines, and 4 patient samples measured by ACCEPT. HER-2neg, HER-2med and HER-2high expressing cells are
defined as mean intensity = 0,�100, and>100 respectively [8]. C. Table showing the number and percentage of HER-
2-positive CTCs in 4 patient samples based on ACCEPT and DEPArray. HER-2-positive cells are subdivided in HER-
2med and HER-2high expressing cells using ACCEPT. D. BioView IF and FISH images of DEPArray-sorted HER-
2-positive and -negative CTCs from patient 1. HER-2-negative CTCs are copy-number neutral (example shown). 7/24
(29%) HER-2-positive CTCs revealed a HER-2/CEP17 ration of 3:2, still being FISH negative (example shown).
https://doi.org/10.1371/journal.pone.0220906.g003
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(n = 10 per cell line). High gene amplification was detected in all visualized cells of HER-2-pos-
itive cell lines KPL-4, IBC-3, SKBR-3, and SUM190 (n = 7 for KPL-4, n = 10 for IBC3, SKBR-
3, and SUM190), with mean HER-2/CEP17 ratios of 5.5 (KPL-4), 6.3 (IBC-3), 8.3 (SKBR-3),
and 4.5 (SUM190). Medium cell line MDA-MB-453 had on average 6 HER-2 and 3 CEP17
copies, being scored as borderline (S1 Fig).
Cell line results were confirmed in an explorative study on four patient samples with high
CTC count. The majority of CTCs were HER-2-negative using DEPArray and ACCEPT (Fig
3C). With DEPArray image analysis, 23.3% of CTCs in patient sample 1 exceeded the HER-
2-positivity threshold. A comparable HER-2med expressing CTC rate was detected by
ACCEPT. In patient samples 3 and 4 we observed 2283 (12.3%) and 1139 (13.1%) HER-2med
expressing CTCs, respectively. In all CellSearch patient samples no HER-2 amplification was
observed. Additionally, CTCs from patient 1 just exceeding the positivity threshold were
DEPArray-sorted. HER-2/neu FISH analysis showed no amplification in these CTCs, although
7/24 (29%) cells visualized, revealed a HER-2/CEP17 ratio of 3:2 (i.e. non-amplified according
to HER-2-FISH guidelines) (Fig 3D).
Our finding that HER-2med expressing cells are mainly scored as negative using visual scor-
ing, and are not HER-2-amplified, is in line with results from a large patient cohort where only
positive CTCs by visual scoring were HER-2-amplified [10].
HER-2 analysis in a MBC patient cohort
Using the objective analysis software of ACCEPT, we studied the distribution of HER-2neg,
HER-2med, and HER-2high expressing CTCs in 45 CellSearch CTC samples containing�5
CTCs from 35 MBC patients. 11/45 (24%) samples came from 10 patients with a HER-2-posi-
tive primary tumor and/or metastasis, and 34/45 (76%) samples came from 25 patients with a
HER-2-negative primary tumor and/or metastasis (Fig 4, S1 Table). In the HER-2-negative
patient group, all first blood samples were taken at the start of a new line (1st-3rd) of therapy
for MBC. None of these patients received any anti-HER-2 directed therapy. From HER-
2-postitive patients, all samples (except from patient 2000) were taken at first line of therapy
for MBC and none of them were at that moment treated with anti-HER-2 directed therapy,
due to various reasons (i.e. de novo MBC; adjuvant trastuzumab had already stopped; or in 1
patient no anti-HER-2 directed therapy had been added to the adjuvant treatment). Sample
2000_1 was taken at the start of the second line of therapy, however the first line did not
include trastuzumab. During further treatment this patient did receive anti-HER-2 directed
therapy, as was the case when sample 2000_2 was taken (S2 Table). We observed in both
groups heterogeneous HER-2 expression patterns. All 10 (100%) patients with HER-2-positive
MBC, had�1 HER-2high expressing CTCs, while in the HER-2-negative MBC patients, this
was in 5/25 (20%) patients (Fisher exact: p< 0.0001). Overall, 37% of patients harbored >10%
HER-2high expressing CTCs. However, when combining HER-2med and HER-2high expressing
CTCs, this was 94% of patients. This is comparable with recent data of 132 patients (39%
HER-2-positive and 61% HER-2-negative patients), where 89.4% of patients had HER-2med
and/or HER-2high expressing CTCs [8].
Focusing on patients with multiple sampling, comparable HER-2neg, HER-2med, and HER-
2high CTC counts were observed. However, in patient 2000, diagnosed with HER-2-positive de
novo MBC, HER-2high expressing CTCs were eliminated after anti-HER-2 directed therapy.
Similarly, in patient 3495, who was diagnosed with HER-2-negative (IHC 2+/FISH-negative)
de novo MBC, 20% of the CTCs were HER-2high expressing at the start of an aromatase inhibi-
tor. Although the CTC burden was comparable, HER-2high expressing CTCs disappeared
completely after 6 weeks on therapy (Fig 4, S2 Table).
HER-2 characterization on circulating tumor cells
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Surprisingly, in all 71 samples containing <5 CTCs, we found no HER-2neg CTCs and
solely HER-2med and HER-2high expressing CTCs, independent of the primary tumor or
metastasis status (S2 Fig). A similar observation was made by Zeune et al, with samples con-
taining solely HER-2med and/or HER-2high CTCs all having�6 CTCs in total [8]. When ana-
lyzing leukocytes, we found in all samples up to 5% of leukocytes did express some HER-2.
This physiological phenomenon will not affect IF image-based HER-2 analysis of CTCs, as
CTCs and leukocytes are measured individually [21].
We aimed to validate the ACCEPT results by applying gene expression analysis on enriched
CTC fractions of blood samples taken simultaneously. ACCEPT image analysis and qRT-PCR
data on CellSearch Profile-enriched CTC fractions were available for 7 cell lines and 54 patient
samples. ERBB2 (HER-2/neu) relative gene expression (RGE) levels in cell lines (S3 Fig) corre-
lated with mean intensity HER-2 IF data, as measured by DEPArray (r = 0.97, p = 0.0002) and
ACCEPT (r = 0.96, p = 0.0007) image analysis. ERBB2 expression, corrected for CTC content,
in 20 patient samples with�5 CTCs (range 5–17502) demonstrated variable ERBB2 RGE (Fig
5), but correlated well with ACCEPT data (r = 0.8255, p< 0.00001). Focusing on HER-2high
expressing CTCs, comparative analysis with ERBB2 RGE data demonstrated how 3/10 (30%)
samples with low ERBB2 RGE (<0.2, i.e. below median RGE) contained HER-2high expressing
CTCs (range 1–2), whereas HER-2high expressing CTCs (range 1–16) were present in 7/10
(70%) samples with high ERBB2 RGE (>0.2) (Fisher exact: p = 0.1789). When focusing on the
samples with a highest ERBB2 expression (RGE >0.34, i.e. above the third quartile) 5/5
patients harbored >20% (i.e. above the third quartile) HER-2high expressing CTCs, while in
the other group this was in 1/15 of patients (Fisher exact: p = 0.0004). Moreover, 5/5 patients
with the highest ERBB2 expression had�1 HER-2high expressing CTC, while this was 5/15 in
the group with a lower ERBB2 RGE (Fisher exact: p = 0.016). We did not observe a correlation
between ACCEPT and qRT-PCR data in samples with <5 CTCs. Taken together, this demon-
strates that in patients with�5 CTCs, qRT-PCR on CellSearch-enriched samples can identify
samples containing HER-2high expressing CTCs.
Fig 4. HER-2 IF scoring by ACCEPT of a MBC patient cohort. Percentage of HER-2neg, HER-2med, and HER-2high
expressing CTCs in a MBC cohort divided in patients with HER-2-positive or -negative tissue (primary tumor and/or
metastasis) samples. Total CTC count per sample is depicted on top. HER-2high expressing CTCs are present in at least
1 sample of 10/10 (100%) HER-2-positive patients, and 5/25 (20%) HER-2-negative patients.
https://doi.org/10.1371/journal.pone.0220906.g004
HER-2 characterization on circulating tumor cells
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Discussion
Personalized targeted treatment of patients with MBC relies on the accurate assessment of spe-
cific molecular aberrations in tumor cells, e.g. the overexpression of the transmembrane HER-
2 receptor. To circumvent potential clinically-relevant discordances in HER-2 receptor status
between archival primary tumor tissue and metastatic lesions, the molecular interrogation of
FDA-cleared CellSearch-enriched CTCs can provide an attractive alternative for real-time bio-
marker assessment [1–3]. However, implementation of CellSearch-based HER-2 analysis
using visual scoring has been limited. Most recently an objective analysis software has been
made available [8], which we compared to other CTC analysis techniques.
Our observer study demonstrated high agreement between the observers and ACCEPT
considering the HER-2neg and HER-2high expressing CTCs, while HER-2med expressing CTCs
by ACCEPT were scored negative by the observers in 89% of CTCs. Moreover, we show that
HER-2med expressing cell line cells and patient CTCs, did not show HER-2/neu gene amplifi-
cation, which is in agreement with literature, were MDA-MB-453 was scored IHC and FISH
negative [8, 9, 11–13, 22]. Both results are in line with data from a large patient cohort where
negative CTCs by visual scoring were HER-2 copy number neutral [10]. As patients only
receive HER-2-directed therapy when HER-2 overexpression is proven on tissue samples (i.e.
IHC 3+ or FISH+), one might argue on the clinical benefit of treating patients harboring
HER-2med expressing CTCs.
When inferring the prevalence of HER-2neg, HER-2med, and HER-2high expressing CTCs in
our patient cohort, we found that one third harbored >10% HER-2high expressing CTCs,
while almost all patients harbored HER-2med expressing CTCs. This is comparable with recent
data on a similar cohort of 132 patients [8]. In daily clinic, HER-2 overexpression (IHC 3+ or
FISH+) is only present in a minority of patients with primary invasive breast cancer, although
a higher incidence of HER-2-positivity is seen in MBC (26,3% in stage IV versus 15% in stage
I-III patients) [23]. This prevalence is in line with the percentage of patients with HER-2high
expressing CTCs in both our and the MBC cohort examined by Zeune et al [8]. Taken
together, we suggest that HER-2high expressing CTCs might be more clinically relevant than
HER-2med expressing CTCs.
Besides all HER-2-positive patients, also 5/25 HER-2-negative patients harbored�1 HER-
2high expressing CTCs based on ACCEPT. This suggests either a shift in HER-2 status in these
5 patients, or outgrowth of a minor HER-2-positive subclone not detected with FISH on tissue
samples. The latter has been demonstrated with FISH on DEPArray sorted primary tumor
Fig 5. HER-2 protein (ACCEPT) versus mRNA (qRT-PCR) expression of MBC patient samples. A. Increasing
ERBB2 (HER-2) relative gene expression (RGE) corrected for CTC content of 20 patient samples with�5 CTCs. B.
Corresponding HER-2med and HER-2high expressing CTC count by ACCEPT of 20 patient samples with�5 CTCs. For
four samples the total number of HER-2med expressing cells is given on top. For six samples�20% of total CTC count
were HER-2high expressing CTCs (◆).
https://doi.org/10.1371/journal.pone.0220906.g005
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samples [24]. One should realize that HER-2 expression on tissue samples is often heteroge-
neous and are given IHC scores of 1+ or 2+. In our cohort, 3 out of 5 patients with discrepant
HER-2 status were assigned IHC 1+ or 2+, suggesting some HER-2-positive tumor cells were
already present at baseline. In general, IHC status (i.e. more homogeneous 0 or 3+, or more
heterogeneous 1+ or 2+) of the archival tumor was not related to the degree of heterogeneity
we found in the CTC samples. Acquisition (i.e. clonal selection/expansion) of HER-2 gene
amplification in CTCs has reported to be associated with cancer progression [25]. Still, 80% of
patients with a HER-2-negative primary tumor did not harbor any HER-2high expressing
CTCs. We argue that in these patients a major clinical impact of HER-2-directed monotherapy
cannot be expected.
Clinical trials incorporating quantitative HER-2 analysis on CTCs might learn us the clin-
ical validity of both HER-2med and HER-2high expressing CTCs. The ongoing DETECT III
trial aims to demonstrate the benefit from Lapatinib therapy in initially HER-2-negative
patients, who are HER-2-positive on CTCs [7]. The CirCe T-DM1 trial showed that HER-2/
neu gene amplification in CTCs from 7 HER-2-negative MBC patients occurs in a minor
CTC subpopulation [26]. Overall a low response rate was reported (1/7), questioning the
clinical utility of anti-HER-2 therapy in patients with HER-2 amplification in a minor subset.
Another phase II trial tested effectiveness of Lapatinib in MBC patients with HER-2-negative
primary tumors and HER-2-positive CTCs analyzed by visual scoring of CellSearch images
and FISH [27]. 7/96 patients, harboring 2–5 CTCs, were eligible (i.e.�50% of CTCs were
HER-2-IF positive, and 1 sample was FISH-positive). No objective tumor responses occurred
in this population, underlining the importance of patient selection for such trials. Based on
our findings this should be patients with�5 CTCs and at least one HER-2high expressing
CTC. To enhance clinical utility of CTC-based therapy selection, it is important to consider
improved quality control, validation, and standardization for HER-2 characterization and
scoring on CTCs, as is required for HER-2 diagnostics on tissue. Objective image analysis is
key start.
Liquid biopsies have the major advantage that they can be taken easily and repeatedly. The
ability to detect ERBB2 gene amplifications in plasma has already been proven [28], however
no trials testing anti-HER-2 directed therapy in MBC based on HER-2 alterations in cell free
(cf)DNA have been performed. Although, efforts have been made in gastric cancer [29]. For
both cfDNA and CTCs (independent of the enrichment technique, i.e. EpCAM based or
marker free) applies: a standardized biomarker should be tested in the right patient population
in a four-armed randomized trial [30, 31] to proof its utility in distinguishing between patients
that will or will not benefit from specific therapies.
Conclusions
Our data shows that HER-2 characterization on CTCs should be focused on HER-2high
expressing CTCs in patient samples containing�5 CTCs. Although CTC-derived HER-2
expression in patients is heterogeneous, the prevalence of patients with�1 HER-2high
expressing CTCs better reflects the incidence of HER-2-positive MBC seen in the clinic.
Additionally, we have demonstrated that only HER-2high expressing tumor cells harbor
amplification of the HER-2/neu gene, and samples containing HER-2high expressing CTCs
show high relative gene expression of HER-2 on qRT-PCR. For both these downstream tech-
niques, prior CTC enrichment is necessary, involving extra cost and labor. Therefore,
straightforward automated images analysis has enormous potential for clinical implementa-
tion. When focusing on the right patient population, CTC-direct anti-HER-2 therapy might
proof itself in clinical trials.
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Supporting information
S1 Table. HER-2 tissue status. IHC (0–3+) and FISH (0 = negative, 1 = positive) results for
primary tumor (PT) and metastatic tissue (MET) per patient.
(TIF)
S2 Table. Line of treatment at time of CTC enumeration. In the HER-2-negative patient
group, all first blood samples were taken at the start of a new line (1st-3rd) of therapy for MBC.
None of these patients received any anti-HER-2 directed therapy. From the HER-2-postitive
patients, all samples were taken at first line of therapy for MBC, but sample 2000_1 (start of
the second line), and none of them were at that moment treated with anti-HER-2 directed
treatment. Sample 2000_2 was taken at the start of the fifth line of therapy, after prior anti-
HER-2 directed therapy.
(TIF)
S3 Table. Methodologies and cut-offs used for image-based analysis of HER-2 fluorescent
intensities.
(TIF)
S1 Fig. BioView IF and FISH images of leukocytes and cell line cells. IF composite image is
taken before FISH. Secondly, Nucleus/DAPI, CEP-17/SpectrumGreen, HER-2-neu/Spectru-
mOrange, and the composite images are shown. Leukocytes, MDA-MB-436, MCF-7, and BT-
20 cells demonstrated a copy-number neutral HER-2/neu status. Mean HER-2/CEP17 ratios
for amplified cell lines were 5.5 (KPL-4), 6.3 (IBC-3), 8.3 (SKBR-3), and 4.5 (SUM190).
Medium cell line MDA-MB-453 had on average 6 HER-2 and 3 CEP17 copies.
(TIF)
S2 Fig. ACCEPT results in <5 CTC patient samples. HER-2neg, HER-2med, and HER-2high
expressing CTC count in a MBC cohort with samples <5CTC, divided in patients with HER-
2-positive or -negative tissue (primary tumor and/or metastasis) samples.
(TIF)
S3 Fig. HER-2 gene expression. ERBB2 relative gene expression (RGE) corrected for house-
keeping gene expression, of bulk samples from 7 cell lines.
(TIF)
S1 Supplementary Methods.
(PDF)
S1 Dataset. RAWdata_HER2_CTC.
(ZIP)
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